Web Application Security in Hyderabad · Pharma SaaS & HITEC City

Hyderabad web-application-security has a uniquely diverse buyer base. Clinical-trial SaaS and eTMF / EDC platform operators in Genome Valley face 21 CFR Part 11 application-layer controls and FDA-aligned audit-trail integrity expectations. HITEC City B2B SaaS and product startups face OWASP ASVS Level 3 + SOC 2 Type II + ISO 27001:2022 enterprise procurement standards. US-healthcare GCCs in Gachibowli and Q City handle US PHI under HIPAA Security Rule §164.308-312 and Business Associate Agreement (BAA) obligations passed down from US parents. Pharma customer-facing portals (patient-engagement apps, eDetailing tablets, medical-information portals) face DPDP and (where US-bound) HIPAA overlays. Macksofy's Hyderabad AppSec practice runs one bench, four sub-playbooks, selected at kickoff per the customer's actual profile.

Clinical-trial SaaS AppSec is the most specialised lane. eTMF (Veeva Vault eTMF, Wingspan, ennov eTMF), EDC (Medidata Rave, OpenClinica, Castor, Veeva Vault CDMS) and clinical-trial-management SaaS face a control surface unique to regulated-data — audit-trail-disable-path testing, ALCOA+ contemporaneity at the application layer, electronic-signature integrity, electronic-record amendment-and-correction control, role-based access matrix tested role-by-role (sponsor / CRO / investigator / monitor / patient), and the consent-flow integrity testing that DPDP §16 and 21 CFR Part 11 §11.30 (for open systems) both require. Most generic AppSec vendors miss these because the scope is not in their playbook.

HITEC City B2B SaaS AppSec follows the OWASP ASVS Level 3 + API Top 10 (2023) playbook with US-customer parent-control overlay. Multi-tenant authz testing at every role boundary (BOLA, tenant-bleed, SCIM impersonation), identity-federation testing (SAML, OIDC, OAuth 2.0 with Okta / Entra ID / AWS Cognito / Google Workspace), cloud-native testing (IaC misconfiguration, CI/CD pipeline trust, AWS / GCP IAM-and-KMS), and (where the customer's threat model surfaces it) LLM application security (OWASP Top 10 for LLM Applications 2025). Reports map to SOC 2 CC6 / CC7 / CC8 + ISO 27001:2022 Annex A inside the next audit window.

US-healthcare GCC AppSec is HIPAA-Business-Associate-flavoured. The customer's BAA imposes specific application-layer controls — PHI encryption at rest and in transit, breach-notification-readiness at the application boundary, access-audit logging integrity, customer-data-egress prevention, and the §164.312 technical safeguards mapped onto the customer-facing application surface. We crosswalk every finding to HIPAA Security Rule §164.308 administrative safeguards (workforce training, access management), §164.310 physical safeguards (where the GCC self-hosts), and §164.312 technical safeguards (access control, audit logs, integrity, transmission security). The deliverable is BAA-compatible operational evidence the US parent's compliance team accepts without rework.

Pharma customer-facing portal AppSec is the fourth playbook layer. Top-5 generics in Hyderabad now run patient-engagement apps, eDetailing tablets, medical-information portals, sample-request portals and HCP-engagement platforms — application surfaces that handle personal data and (in some cases) protected-health information. DPDP Act compliance overlay applies, HIPAA applies where the app surface handles US-bound data, and 21 CFR Part 11 §11.30 applies where the application is part of a GxP open system. Each scope is reconciled with the customer's QA director (because the validation-state question can attach to any application that touches GxP data).

Identity is the cross-cutting concern. Hyderabad clients run hybrid identity (on-premises AD federated to Azure AD / Okta / OneLogin) with multiple regional-language frontends, lab-network-isolated identity domains for pharma, and CRO-sponsor-side federated identity for clinical-trial-portal access. AppSec scope tests federation trust paths end-to-end — SCIM trust, SAML metadata signing, OIDC discovery integrity, JWT algorithm confusion at the API gateway, MFA-fatigue / push-bombing resistance and the privileged-access path discovery that almost always exists. Findings are dated against the next SOC 2 Type II + HIPAA review.

Procurement reality matters. Clinical-trial SaaS and pharma customer-portal procurement closes through the IT head and the QA director, with the head of clinical operations or medical affairs copied depending on scope. HITEC City SaaS procurement closes through the CTO and AppSec lead in a single weekly sync. US-healthcare GCC procurement closes through the Indian CISO with the US parent's regional CISO copied; the engagement-letter clauses align to the US parent's third-party-AppSec standard. Pharma engagements layer in the QA-witness scheduling for any validated application; the no-state-alteration acknowledgement is standard.

Onsite cadence — HITEC City regional hub means two-hour onsite SLA across Madhapur, Gachibowli, Banjara Hills, Kondapur and Genome Valley. Patancheru / Bachupally / Shameerpet sites are 60-90 minutes from the hub. AppSec engagement length is typically 3-4 weeks for HITEC City SaaS scope, 4-5 weeks for clinical-trial SaaS, 4-5 weeks for US-healthcare GCC scope, and 5-6 weeks for pharma customer-portal scope with multi-surface coverage. Most engagements include one onsite kickoff and one onsite closing readout with the remainder running remote via the customer's preferred async channel.